Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Centrica swings to interim statutory operating loss

(Sharecast News) - Energy and services firm Centrica said on Thursday that it had swung to a statutory operating loss in the six months ended 30 June. Centrica reported a statutory operating loss of £69.0m in H125, down from H124's £1.67bn operating profit and including a net loss on re-measurements of derivative energy contracts and impairments of assets of £618.0m, while adjusted underlying earnings fell from £1.43bn to £900.0m amid "a challenging backdrop". Statutory losses per share came to 5.1p, down from FY24's statutory earnings per share of 25.1p.

The FTSE 100-listed group said net operating cash flow sank from £798.0m to £294.0m, while net cash from investing activities fell from £183.0m to £13.0m, free cash flow dropped from £816.0m to £244.0m, and net cash contracted from £3.21bn to £2.49bn. Capital expenditure, on the other hand, rose from £221.0m to £244.0m.

However, Centrica increased its interim dividend by 22% to 1.83p, in line with the company's intention to raise its FY dividend to 5.5p per share.

Customer numbers increased by 81,000 in British Gas Energy residential, including net organic growth of 12,000, by 17,000 in Bord Gáis Energy and by 7,000 in small business customer sites.

Chief executive Chris O'Shea said: "I'm pleased with the progress we've made in some areas during the first half despite a challenging backdrop."

As of 0820 BST, Centrica shares were down 0.79% at 157.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.